Literature DB >> 20978383

The future of HIV vaccine research and the role of the Global HIV Vaccine Enterprise.

Yegor Voronin1, Amapola Manrique, Alan Bernstein.   

Abstract

PURPOSE OF REVIEW: This review covers the role of the Global HIV Vaccine Enterprise (the Enterprise), an alliance of independent organizations committed to development of a safe and effective HIV vaccine. It discusses the history, impact on the field, and future directions and initiatives of the alliance in the context of recent progress in HIV vaccine research and development. RECENT
FINDINGS: Significant progress has been made in the field since the release of the 2005 Scientific Strategic Plan (the Plan) of the Enterprise. Over the last year, the Enterprise embarked on an impact assessment of the 2005 Plan and the development of the 2010 Plan. Enterprise Working Groups identified key priorities in the field, several of which are discussed in this review, including changing the nature, purpose and process of clinical trials, increasing and facilitating data sharing, and optimizing existing and mobilizing new resources.
SUMMARY: This time is an important moment in HIV vaccine research. New clinical trial and laboratory results have created new opportunities to advance the search for an HIV vaccine and reinvigorated the field. The Enterprise will publish its 2010 Plan this year, providing a framework for setting new priorities and directions and encouraging new and existing partners to embark on a shared scientific agenda.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20978383      PMCID: PMC2974435          DOI: 10.1097/COH.0b013e32833cfe32

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  14 in total

1.  Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques.

Authors:  Yongjun Sui; Qing Zhu; Susan Gagnon; Amiran Dzutsev; Masaki Terabe; Monica Vaccari; David Venzon; Dennis Klinman; Warren Strober; Brian Kelsall; Genoveffa Franchini; Igor M Belyakov; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-10       Impact factor: 11.205

2.  Medicine. The need for a global HIV vaccine enterprise.

Authors:  Richard D Klausner; Anthony S Fauci; Lawrence Corey; Gary J Nabel; Helene Gayle; Seth Berkley; Barton F Haynes; David Baltimore; Chris Collins; R Gordon Douglas; Jose Esparza; Donald P Francis; N K Ganguly; Julie Louise Gerberding; Margaret I Johnston; Michel D Kazatchkine; Andrew J McMichael; Malegapuru W Makgoba; Giuseppe Pantaleo; Peter Piot; Yiming Shao; Edmund Tramont; Harold Varmus; Judith N Wasserheit
Journal:  Science       Date:  2003-06-27       Impact factor: 47.728

3.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

Authors:  Neil M Flynn; Donald N Forthal; Clayton D Harro; Franklyn N Judson; Kenneth H Mayer; Michael F Para
Journal:  J Infect Dis       Date:  2005-01-27       Impact factor: 5.226

4.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Authors:  Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Joseph Chiu; Robert Paris; Nakorn Premsri; Chawetsan Namwat; Mark de Souza; Elizabeth Adams; Michael Benenson; Sanjay Gurunathan; Jim Tartaglia; John G McNeil; Donald P Francis; Donald Stablein; Deborah L Birx; Supamit Chunsuttiwat; Chirasak Khamboonruang; Prasert Thongcharoen; Merlin L Robb; Nelson L Michael; Prayura Kunasol; Jerome H Kim
Journal:  N Engl J Med       Date:  2009-10-20       Impact factor: 91.245

5.  Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.

Authors:  Brandon F Keele; Elena E Giorgi; Jesus F Salazar-Gonzalez; Julie M Decker; Kimmy T Pham; Maria G Salazar; Chuanxi Sun; Truman Grayson; Shuyi Wang; Hui Li; Xiping Wei; Chunlai Jiang; Jennifer L Kirchherr; Feng Gao; Jeffery A Anderson; Li-Hua Ping; Ronald Swanstrom; Georgia D Tomaras; William A Blattner; Paul A Goepfert; J Michael Kilby; Michael S Saag; Eric L Delwart; Michael P Busch; Myron S Cohen; David C Montefiori; Barton F Haynes; Brian Gaschen; Gayathri S Athreya; Ha Y Lee; Natasha Wood; Cathal Seoighe; Alan S Perelson; Tanmoy Bhattacharya; Bette T Korber; Beatrice H Hahn; George M Shaw
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-19       Impact factor: 11.205

6.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

Authors:  Susan P Buchbinder; Devan V Mehrotra; Ann Duerr; Daniel W Fitzgerald; Robin Mogg; David Li; Peter B Gilbert; Javier R Lama; Michael Marmor; Carlos Del Rio; M Juliana McElrath; Danilo R Casimiro; Keith M Gottesdiener; Jeffrey A Chodakewitz; Lawrence Corey; Michael N Robertson
Journal:  Lancet       Date:  2008-11-13       Impact factor: 79.321

7.  Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans.

Authors:  Troy D Querec; Rama S Akondy; Eva K Lee; Weiping Cao; Helder I Nakaya; Dirk Teuwen; Ali Pirani; Kim Gernert; Jiusheng Deng; Bruz Marzolf; Kathleen Kennedy; Haiyan Wu; Soumaya Bennouna; Herold Oluoch; Joseph Miller; Ricardo Z Vencio; Mark Mulligan; Alan Aderem; Rafi Ahmed; Bali Pulendran
Journal:  Nat Immunol       Date:  2008-11-23       Impact factor: 25.606

8.  Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Authors:  Laura M Walker; Sanjay K Phogat; Po-Ying Chan-Hui; Denise Wagner; Pham Phung; Julie L Goss; Terri Wrin; Melissa D Simek; Steven Fling; Jennifer L Mitcham; Jennifer K Lehrman; Frances H Priddy; Ole A Olsen; Steven M Frey; Phillip W Hammond; Stephen Kaminsky; Timothy Zamb; Matthew Moyle; Wayne C Koff; Pascal Poignard; Dennis R Burton
Journal:  Science       Date:  2009-09-03       Impact factor: 47.728

9.  Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys.

Authors:  Philip R Johnson; Bruce C Schnepp; Jianchao Zhang; Mary J Connell; Sean M Greene; Eloisa Yuste; Ronald C Desrosiers; K Reed Clark
Journal:  Nat Med       Date:  2009-05-17       Impact factor: 53.440

10.  The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan.

Authors: 
Journal:  PLoS Med       Date:  2005-01-18       Impact factor: 11.069

View more
  4 in total

1.  Early immunologic correlates of HIV protection can be identified from computational analysis of complex multivariate T-cell flow cytometry assays.

Authors:  Nima Aghaeepour; Pratip K Chattopadhyay; Anuradha Ganesan; Kieran O'Neill; Habil Zare; Adrin Jalali; Holger H Hoos; Mario Roederer; Ryan R Brinkman
Journal:  Bioinformatics       Date:  2012-02-29       Impact factor: 6.937

2.  Current status of multiple antigen-presenting peptide vaccine systems: Application of organic and inorganic nanoparticles.

Authors:  Yoshio Fujita; Hiroaki Taguchi
Journal:  Chem Cent J       Date:  2011-08-23       Impact factor: 4.215

3.  A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV).

Authors:  Yen-Ju Shen; Enid Shephard; Nicola Douglass; Nicolette Johnston; Craig Adams; Carolyn Williamson; Anna-Lise Williamson
Journal:  Virol J       Date:  2011-05-30       Impact factor: 4.099

4.  Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.

Authors:  Richard Stebbings; Michèle Février; Bo Li; Clarisse Lorin; Marguerite Koutsoukos; Edward Mee; Nicola Rose; Joanna Hall; Mark Page; Neil Almond; Gerald Voss; Frédéric Tangy
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.